Explore the vast range of titles available.

We analyzed feature-tracking derived circumferential and longitudinal strain in healthy volunteers who underwent cardiac magnetic resonance imaging (CMR) at 3.0 T. 88 healthy adults (44.6 ± 18.0 years old, 49% male), without prior cardiovascular disease, underwent CMR at 3.0 T including cine, and late gadolinium enhancement in subjects >45 years. LV functional analysis and feature-tracking strain analyses were carried out. Global strain had better reproducibility than segmental strain. There was a sex specific difference global longitudinal strain (mean ± SD, −18.48 ± 3.65% (male), −21.91 ± 3.01% (female), p < 0.001), but not global circumferential strain (mean ± SD, −25.41 ± 4.50% (male), −27.94 ± 3.48% (female), p = 0.643). There was no association of strain with ageing after accounting for sex for both global longitudinal and circumferential strain. Feature-tracking strain analysis is feasible at 3.0 T. Healthy female volunteers demonstrated higher magnitudes of global longitudinal strain when compared to male counterparts. Whilst global cine-strain has good reproducibility, segmental strain does not.

Arteriovenous fistula (AVF) is the preferred type of vascular access for maintenance haemodialysis but it may contribute to maladaptive cardiovascular remodelling. We studied the effect of AVF creation on cardiac structure and function in patients with chronic kidney disease (CKD). In this prospective cohort study patients with CKD listed for first AVF creation underwent cardiac magnetic resonance (CMR) imaging at baseline and at 6 weeks. All participants had ultrasound measurements of fistula blood flow at 6 weeks. The primary outcome was the change in left ventricular (LV) mass. Secondary outcomes included changes in LV volumes, LV ejection fraction, cardiac output, LV global longitudinal strain and N-terminal-pro B-type natriuretic peptide (NT-proBNP). A total of 55 participants were enrolled, of whom 40 (mean age 59 years) had AVF creation and completed both scans. On the second CMR scan, a mean increase of 7.4 g (95% CI 1.1–13.7, p = 0.02) was observed in LV mass. Significant increases in LV end-diastolic volumes (p = 0.04) and cardiac output (p = 0.02) were also seen after AVF creation. No significant changes were observed in LV end-systolic volumes, LV ejection fraction, NT-proBNP and LV global longitudinal strain. In participants with fistula blood flows ≥ 600 mL/min (n = 22) the mean increase in LV mass was 15.5 g (95% CI 7.3–23.8) compared with a small decrease of 2.5 g (95% CI − 10.6 to 5.6) in participants with blood flows < 600 mL/min (n = 18). Creation of AVF for haemodialysis resulted in a significant increase of LV myocardial mass within weeks after surgery, which was proportional to the fistula flow.

BackgroundVascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents, but are associated with cancer therapy-related cardiac dysfunction (CTRCD) and hypertension. The timing, frequency and magnitude of these toxicities are poorly defined. The objective of this study is therefore to investigate the incidence, time course and mechanisms of VEGFI-associated CTRCD and hypertension.MethodsPatients commencing VEGFI underwent blood pressure (BP) monitoring, echocardiography and cardiac biomarker measurement at baseline and prospectively over 24 weeks. Serial adenosine stress perfusion cardiovascular MRI (CMR) was performed in a substudy. CTRCD was defined as left ventricular ejection fraction (LVEF) decline by ≥10 percentage points from baseline to a value <50%.Results78 patients participated (68% men; age 63±11 years). 15 patients (19%) developed CTRCD, and it was evident at 4 weeks in 93% of cases. Overall, LVEF was 4.2% (95% CI: −6.2% to −2.3%, p<0.001) lower than baseline at 4 weeks. At 4 weeks, N-terminal pro-brain natriuretic peptide, but not troponin, was higher in patients with CTRCD. 62 (77%) patients developed hypertension. Home systolic and diastolic BP increased by 7.2 mm Hg (4.7–9.8, p<0.001) and 4.8 mm Hg (3.1–6.5, p<0.001), respectively, at 1 week. There was no association between change in LVEF and BP.CMR-derived LVEF, T1 relaxation times and resting myocardial blood flow (n=46) were 5.2% (−7.3% to −3.1%, p<0.001), 27 ms (−40 to −14, p<0.001) and 14.7 mL/100mL/min (−24.2 to −5.1, p=0.004), respectively, lower at 4 weeks.ConclusionVEGFI-associated CTRCD is frequent and occurs early. This finding has implications for prioritising early cardiac imaging follow-up after commencing treatment. Underlying mechanisms include myocardial and microvascular effects that are at least partly independent of hypertension.

Rapid access chest pain (RACP) clinics are designed to expedite cardiac assessment, but current pathways cause delays due to sequential consultations and testing. This pilot evaluated a novel direct-to-CT coronary angiography (CTCA) pathway to test the hypothesis that a 'test-first' model would reduce the time to diagnosis and clinic utilisation. This was a prospective single-centre pilot of consecutive primary care referrals to an RACP service (June 2024-January 2025). Eligible patients with suspected anginal symptoms, no known coronary artery disease (CAD) and no contraindications to CTCA were offered an opt-in to a direct-to-CTCA pathway. CTCA was performed using a prospective single-heartbeat acquisition. The primary outcome was referral-to-diagnosis interval. Secondary outcomes included need for face-to-face consultation, further investigations, incidental findings and theoretical cost savings. 149 patients (mean age 57±9 years, 34% female) underwent CTCA. Median referral-to-diagnosis interval was 29 days (IQR 21-41) vs 88 days (IQR 84-101) in the conventional pathway. CTCA revealed no or mild CAD in 104 (70%) patients; only 47 (32%) required subsequent face-to-face review. Follow-up testing included exercise ECG (17%), echocardiography (8%) and invasive coronary angiography (7%). Incidental findings were uncovered in 30%, with 3% leading to specialty referral. An estimated 102 outpatient visits were avoided, with a cost avoidance estimate of £32 620 per year. A direct-to-CTCA pathway for patients with suspected cardiac chest pain is feasible, reduces time to diagnosis and aligns with National Institute for Health and Care Excellence guidelines. The pathway enables early CAD exclusion in most patients, reduces unnecessary clinic visits and optimises resource use without compromising diagnostic quality.

Chronic kidney disease (CKD) and cardiovascular disease share common risk factors such as hypertension, diabetes mellitus and dyslipidemia. Patients with CKD carry a high burden of cardiovascular disease and may be excluded from clinical trials on the basis of safety. There are an increasing number of clinical trials which predefine sub-group analysis for CKD. This systematic review with fixed-effect meta-analysis investigates glucose lowering therapy and cardiovascular outcomes in relation to CKD. We included randomized controlled trials (RCT) of glucose lowering treatments performed in adults (aged≥18 years), humans, with no restriction on date, and English-language restriction in patients with pre-existing CKD regardless of diabetes status. Embase & Ovid Medline databases were searched up to April 2021. Risk of bias was assessed according to Revised Cochrane risk-of-bias tool. We included 7 trials involving a total of 48,801 participants. There were 4 sodium-glucose cotransporter-2 inhibitors (SGLT2i), 2 glucagon-like peptide-1 receptor (GLP-1R) agonists and 1 Dipeptidyl-peptidase 4 (DPP4) inhibitor identified. SGLT2i (relative risk (RR) = 0.90, 95% confidence interval (CI) [0.79–1.02]) and GLP-1R agonists (RR = 0.83, 95% CI [0.72–0.96]) were associated with a reduction in cardiovascular death. SGLT2i (RR = 0.69, 95% CI [0.63–0.75]) are also associated with a reduction in hospitalization for heart failure. In summary, this meta-analysis of large, RCTs of glucose lowering therapies has demonstrated that treatment with SGLT2i or GLP-1R agonists may improve 3 point-MACE and cardiovascular outcomes in patients with chronic renal failure compared with placebo. This systematic review was registered with the PROSPERO network (registration number: CRD42021268563) and follows the PRISMA guidelines on systematic reviews and metanalysis.

Background There are few data on the longer-term illness trajectory of patients following hospitalisation for COVID-19. Methods We prospectively enrolled 267 adults hospitalised for COVID-19. Longer-term follow up was available for 260 participants. Event rates for death or unplanned hospitalisation were calculated using a Poisson model. Univariate and multivariable analyses identified baseline predictors, with a backward selection process for the best fitting model. Results The mean age of COVID-19 participants was 54.9±12.1 years, and 41% were female. During median follow-up of 1028 days (IQR:1000,1085), 112 individuals (43.1%) had at least one event including 6 deaths (2.3%). There were 252 events in total. The first event rate was 18.9 per 100 person-years (95%CI: 15.7, 22.8). Multivariable predictors included healthcare worker status (HR 0.59, 95%CI: 0.34, 1.02, p=0.046), Charlson Comorbidity Index (HR 1.13, 95%CI: 1.02, 1.24, p=0.020), current smoking (HR 2.49, 95%CI: 1.21, 5.11, p=0.010), and haemoglobin (HR 0.93, 95%CI: 0.88, 0.99, p=0.020). The WHO Clinical Severity Score was not a significant predictor (p=0.187). Conclusion Comorbidity, current smoking status and haemoglobin predict illness trajectory following hospitalisation for COVID-19, rather than illness severity during hospitalisation. Further research is needed to explore interventions targeting these factors to improve prognosis. Trial registration CISCO-19; http://NCT04403607. Registration date; 23/05/2020

A prospective clinical study evaluating patients 28–60 days after hospitalization for COVID-19 reveals increased cardio-renal inflammation, reduced lung function and poorer self-reported clinical outcomes in patients relative to that in control participants.

Background Mapping of left ventricular (LV) native T1 is a promising non-invasive, non-contrast imaging biomarker. Native myocardial T1 times are prolonged in patients requiring dialysis, but there are concerns that the dialysis process and fluctuating fluid status may confound results in this population. We aimed to assess the changes in cardiac parameters on 3T cardiovascular magnetic resonance (CMR) before and after haemodialysis, with a specific focus on native T1 mapping. Methods This is a single centre, prospective observational study in which maintenance haemodialysis patients underwent CMR before and after dialysis (both scans within 24 h). Weight measurement, bio-impedance body composition monitoring, haemodialysis details and fluid intake were recorded. CMR protocol included cine imaging and mapping native T1 and T2. Results Twenty-six participants (16 male, 65 ± 9 years) were included in the analysis. The median net ultrafiltration volume on dialysis was 2.3 L (IQR 1.8, 2.5), resulting in a median weight reduction at post-dialysis scan of 1.35 kg (IQR 1.0, 1.9), with a median reduction in over-hydration (as measured by bioimpedance) of 0.75 L (IQR 0.5, 1.4). Significant reductions were observed in LV end-diastolic volume (− 25 ml, p = 0.002), LV stroke volume (− 13 ml, p = 0.007), global T1 (21 ms, p = 0.02), global T2 (− 1.2 ms, p = 0.02) following dialysis. There was no change in LV mass (p = 0.35), LV ejection fraction (p = 0.13) or global longitudinal strain (p = 0.22). On linear regression there was no association between baseline over-hydration (as defined by bioimpedance) and global native T1 or global T2, nor was there an association between the change in over-hydration and the change in these parameters. Conclusions Acute changes in cardiac volumes and myocardial native T1 are detectable on 3T CMR following haemodialysis with fluid removal. The reduction in global T1 suggests that the abnormal native T1 observed in patients on haemodialysis is not entirely due to myocardial fibrosis.

Background Post-COVID-19 syndromes have associated with female sex, but the pathophysiological basis is uncertain. Aim There are sex differences in myocardial inflammation identified using cardiac magnetic resonance (CMR) in post-COVID-19 patients, and in patient reported health outcomes following COVID-19 infection. Design This prospective study investigated the time-course of multiorgan injury in survivors of COVID-19 during convalescence. Methods Clinical information, blood biomarkers, and patient reported outcome measures were prospectively acquired at enrolment (visit 1) and 28–60 days post-discharge (visit 2). Chest computed tomography (CT) and CMR were performed at visit 2. Follow-up was carried out for serious adverse events, including death and rehospitalization. Results Sixty-nine (43%) of 159 patients recruited were female. During the index admission, females had a lower peak C-reactive protein (74 mg/l (21,163) versus 123 mg/l (70, 192) p  = 0.008) and peak ferritin (229 μg/l (103, 551) versus 514 μg/l (228, 1122) p  < 0.001). Using the Modified Lake-Louise criteria, females were more likely to have definite evidence of myocardial inflammation (54% (37/68) versus 33% (30/90) p  = 0.003). At enrolment and 28–60 days post-discharge, enhanced illness perception, higher levels of anxiety and depression and lower predicted maximal oxygen utilization occurred more commonly in women. The mean (SD, range) duration of follow-up after hospital discharge was 450 (88) days (range 290, 627 days). Compared to men, women had lower rates of cardiovascular hospitalization (0% versus 8% (7/90); p  = 0.018). Conclusions Women demonstrated worse patient reported outcome measures at index admission and 28–60 days follow-up though cardiovascular hospitalization was lower.

Aims Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium‐glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. Methods and results EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS‐MI) is a randomized, double‐blind, placebo‐controlled, multi‐centre trial designed to assess the effect of empagliflozin on cardiac remodelling evaluated using cardiovascular magnetic resonance (CMR) in 100 patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by CMR. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome will be change in left ventricular end‐systolic volume indexed to body surface area over 24 weeks from randomization. Secondary endpoints include measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and circulating cardiac biomarkers. Conclusions EMPRESS‐MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.